Intraoperative high dose dexamethasone is associated with clinically relevant postoperative pancreatic fistula: a retrospective cohort study
HPB · 2025
DOI: 10.1016/j.hpb.2025.08.008 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift HPB, 2025. Verfasst von Scott C Fligor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Dexamethasone, Pancreatic Fistula, Pancreaticoduodenectomy, Pancreatectomy. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Intraoperative dexamethasone is routinely administered to prevent postoperative nausea and vomiting. Limited research has investigated dexamethasone safety during pancreatectomy. We investigated whether intraoperative dexamethasone administration affects clinically relevant postoperative pancreatic fistula (CR-POPF) development. METHODS: We performed a retrospective cohort study of patients undergoing pancreatoduodenectomy or distal pancreatectomy at a single academic institution (2014-2021). Impact of dexamethasone administration on CR-POPF (ISGPF Grade B/C) was assessed using multivariable logistic regression and inverse probability weighted regression analysis. RESULTS: 503 patients were included (pancreatoduodenectomy n=307; distal pancreatectomy n=196). Of these, 59 (11.7%) received low-dose dexamethasone (4-6 mg) and 100 (19.9%) received high-dose dexamethasone (8-10 mg). High dose dexamethasone (aOR:2.47, 95% CI:1.40-4.36), but not low dose dexamethasone (aOR:1.32, 95% CI:0.61-2.86), was associated with increased odds of CR-POPF. After inverse probability weighted regression adjustment, the average treatment effect of high dose dexamethasone on CR-POPF was +11.1% (95% CI:1.7-20.3%) above the baseline risk of 12.5% (95% CI:9.0-16.1%) in patients receiving no dexamethasone. DISCUSSION: Intraoperative administration of high dose (8-10mg) dexamethasone was associated with a meaningfully increased risk of CR-POPF after pancreatectomy. High-dose dexamethasone is a modifiable risk factor for CR-POPF and should be avoided unless there is clear clinical indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Center for Anesthesia Research Excellence, Beth Israel Deaconess Medical Center,…
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: tkent@bidmc.harvard.edu.
Zitieren
APA
Fligor, S. C., Polanco-Santana, J. C., Lanys, A., Kasakewitch, J. P. G., Schaefer, M. S., Sarpel, U., & Kent, T. S. (2025). Intraoperative high dose dexamethasone is associated with clinically relevant postoperative pancreatic fistula: a retrospective cohort study. HPB. https://doi.org/10.1016/j.hpb.2025.08.008
Vancouver
Fligor SC, Polanco-Santana JC, Lanys A, Kasakewitch JPG, Schaefer MS, Sarpel U, et al. Intraoperative high dose dexamethasone is associated with clinically relevant postoperative pancreatic fistula: a retrospective cohort study. HPB. 2025. doi:10.1016/j.hpb.2025.08.008
BibTeX
@article{Fligor2025,
author = {Fligor, Scott C and Polanco-Santana, John Christopher and Lanys, Ashley and Kasakewitch, Joao P G and Schaefer, Maximilian S and Sarpel, Umut and Kent, Tara S},
title = {Intraoperative high dose dexamethasone is associated with clinically relevant postoperative pancreatic fistula: a retrospective cohort study},
journal = {HPB},
year = {2025},
doi = {10.1016/j.hpb.2025.08.008}
}
EUVIMED